Drug news
Afinitor+ Aromasin combination fails BOLERO-2 study in Breast Cancer - Novartis + Pfizer
The combination of Afinitor (everolimus) from Novartis and Aromasin (exemestane) from Pfizer failed to reach statistical significance in the secondary endpoint of overall survival during the BOLERO-2 trial. Data were presented at the European Breast Cancer Conference in Glasgow.
Median survival in women with advanced oestrogen receptor positive Breast Cancer was 31 months for the combination compared to 26.6 months for those on Aromasin monotherapy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.